Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia - 26/08/11
FINASTERIDE STUDY GROUP
Abstract |
Objectives |
To summarize the 6-year clinical trial data with finasteride. Benign prostatic hyperplasia is a chronic and progressive disease and therefore assessment of long-term safety and efficacy is important.
Methods |
The North American and International Phase III Finasteride trials enrolled symptomatic men with enlarged prostate glands. The initial 1-year placebo-controlled study was followed by a 5-year open-label extension. In total, 6-year finasteride data were available in 487 patients originally randomized to finasteride, and 5-year data were available on 238 patients originally randomized to placebo.
Results |
After 6 years of treatment with finasteride 5 mg, the mean quasi-American Urological Association Symptom Score improved by 4.0 points, the median prostate volume decreased by 24%, and the mean maximal urinary flow rate increased by 2.9 mL/s (P <0.001 for all parameters). Long-term finasteride treatment was well tolerated, with a low incidence of drug-related sexual adverse events occurring during the first year and even fewer occurrences during the 5-year open extension.
Conclusions |
Treatment with finasteride leads to durable improvement in urinary tract symptoms, flow rate, and prostate volume, with no increase in the prevalence of drug-related adverse events over time.
Le texte complet de cet article est disponible en PDF.Plan
 | A complete list of the Finasteride 6-year Study Group can be found in the Appendix. This study was funded by Merck & Co., Inc. F. C. Lowe is a member of the medical advisory board to, and study investigator funded by, the sponsor. J. D. McConnell, P. B. Hudson, N. A. Romas, R. Boake, M. Lieber, M. Elhilali, J. Geller, J. Imperto-McGinely, G. L. Andriole, R. C. Bruskewitz, P. C. Walsh, G. Bartsch, and J. N. Nacey are study investigators funded by the sponsor. S. Shah, F. Pappas, A. Ko, T. Cook, E. Stoner, and J. Waldstreicher are employees of, and hold stock in, the sponsor. |
Vol 61 - N° 4
P. 791-796 - avril 2003 Retour au numéro
Article précédent
- Nocturia and benign prostatic hyperplasia
- Koji Yoshimura, Hiroki Ohara, Kentaro Ichioka, Naoki Terada, Yoshiyuki Matsui, Akito Terai, Yoichi Arai
- Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction
- P.o Hui Chiang, Yao Chi Chuang, Chao Cheng Huang, Chin Pei Chiang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?